Crossover til alternativ behandling var tilladt, hvis patienten viste tegn på sygdomsprogression eller intolerans, som ikke kunne håndteres med dosismodifikation.
Crossover to the alternative treatment arm was allowed if patients showed evidence of disease progression or intolerance that could not be managed by dose modification.